Although there are no experimental prognostic studies on these hubs in BLCA, a study on renal cell carcinoma (RCC) found that C4B suppression was associated with increased survival in patients receiving cytokine therapy, and a deficiency of C4B in stage IV RCC patients was linked to better survival [48]. This evidence concerns the gene C4B and bladder transitional cell carcinoma.